The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 receptor agonist retatrutide. https://siobhanpvif135198.blogerus.com/60839943/glp-3-retatrutide-a-comparative-analysis